2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbidities
2002
β-Blocker Therapy in Heart Failure: Scientific Review
Foody JM, Farrell MH, Krumholz HM. β-Blocker Therapy in Heart Failure: Scientific Review. JAMA 2002, 287: 883-889. PMID: 11851582, DOI: 10.1001/jama.287.7.883.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureClinical trialsFailure patientsClinical outcomesClass IIDrug Administration indicationsBeta-blocker usePrimary end pointΒ-blocker therapyScientific rationaleTreatment of patientsCare of patientsEnglish-language articlesPotential physiologic roleBasic science studiesClass of agentsSystolic dysfunctionMortality benefitPlacebo treatmentDATA EXTRACTIONClinical guidelinesSTUDY SELECTIONCurrent recommendationsPatients